Why the study?
Does torasemide improve cardiac sympathetic nerve activity and left ventricular remodeling compared to furosemide in patients with non-ischaemic congestive heart failure?
Does torasemide improve cardiac sympathetic nerve activity and left ventricular remodeling compared to furosemide in patients with non-ischaemic congestive heart failure?
Torasemide, but not furosemide, improves cardiac sympathetic nerve activity and left ventricular remodeling in patients with non-ischemic heart failure.
Answers are grounded in this paper and cite their sources.
Supports torasemide over furosemide in non-ischemic HF; extends RCT evidence on loop diuretic selection to sympathetic and remodeling endpoints.
OBJECTIVE: To determine the effect of torasemide, a loop diuretic with antialdosteronergic properties, compared with furosemide on cardiac sympathetic nerve activity in patients with congestive heart failure (CHF). METHODS: 40 patients with non-ischaemic CHF (left ventricular ejection fraction (LVEF) < 45%) were randomly assigned to torasemide (4-8 mg/day; n = 20) or furosemide (20-40 mg/day; n = 20). All patients were also treated with angiotensin-converting enzyme inhibitor. The delayed heart to mediastinum count (H/M) ratio, delayed total defect score (TDS) and washout rate were determined from iodine-123 meta-iodobenzylguanidine measured before and 6 months after treatment. Left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV) and LVEF were also determined by echocardiography. RESULTS: After treatment, in patients receiving torasemide, TDS decreased from 44 (8) to 36 (8) (p < 0.001), H/M ratio increased from 1.61 (0.19) to 1.77 (0.24) (p < 0.001), and washout rate decreased from 52 (12)% to 41 (14)% (p = 0.001). In addition, LVEDV decreased from 173 (22) ml to 147 (30) ml (p < 0.001) and LVESV decreased from 117 (19) ml to 95(24) ml (p < 0.001). Although LVEF tended to increase, the change was not significant (from 31 (7)% to 34 (7)%, NS). Conversely, these parameters did not change significantly in patients receiving furosemide. Moreover, percentage change of TDS was significantly correlated with percentage change of LVEDV (r = 0.473, p < 0.05) and of LVESV (r = 0.579, p < 0.01) after torasemide treatment. CONCLUSION: These findings indicate that torasemide treatment can ameliorate cardiac sympathetic nerve activity and left ventricular remodelling in patients with CHF.
No takes yet. Share an insight, caveat, or question.
Shu Kasama (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: